Buscar
Biogen Inc
BIIBAñadir a la lista de seguimiento
199.590USD
+2.400+1.22%
Cierre 06/24, 16:00（ET）Cotizaciones retrasadas 15 min
29.47BCap. mercado
21.35P/E TTM
Más Datos de Biogen Inc Compañía
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Información de Biogen Inc
Símbolo de cotizaciónBIIB
Nombre de la empresaBiogen Inc
Fecha de salida a bolsaSep 17, 1991
Director ejecutivoViehbacher (Christopher A)
Número de empleados7605
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 17
Dirección225 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono17814642000
Sitio Webhttps://www.biogen.com/
Símbolo de cotizaciónBIIB
Fecha de salida a bolsaSep 17, 1991
Director ejecutivoViehbacher (Christopher A)
Ejecutivos de Biogen Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.89K
+16.92%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.04K
-0.01%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
6.45K
+31.09%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
6.37K
+7.60%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Biogen Inc?
Los cinco principales accionistas de Biogen Inc son: Ms. Susan H. Alexander, Esq., J.D.
¿Cuántas instituciones poseen acciones de Biogen Inc (BIIB)?
A fecha de 2026Q1, 2085 instituciones poseen acciones de Biogen Inc, con un valor de mercado combinado de aproximadamente 144.76M, lo que representa el 98.05% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3983853.00.
¿Cuál es la mayor fuente de ganancias de Biogen Inc?
El 2026Q1, el segmento empresarial Spinal Muscular Atrophy-SPINRAZA generó la ganancia más alta para Biogen Inc, ascendiendo a 2.15B y representando el 21.78% de la ganancia total.
